

FORM PTO-1449

ATTY. DOCKET NO.  
37851-922SERIAL NO.  
10/658,834CONFIRM NO.  
7681

# OFFICE OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

APPLICANT  
GANTIER et al.CUSTOMER NO.  
24961FILING DATE  
September 8, 2003GROUP  
1644

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all International applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
/EGS/	A	0	1	2	9	2	0	3	07/10/03	Vega et al.	424	233.1	12/17/01
	B	0	1	2	9	5	8	4	07/10/03	Vega	435	5	12/13/00
	C	0	1	3	4	3	5	1	07/17/03	Vega et al.	435	69.1	12/17/01
	D	0	1	7	5	6	9	4	09/18/03	Vega	435	5	05/04/01
	E	3	2	2	4	4	0	4	12/04/03	Vega et al.	435	6	02/24/03
	F	4	0	4	4	1	2	6	08/23/77	Cook et al.	424	243	07/09/76
	G	4	3	6	4	9	2	3	12/21/82	Cook et al.	424	46	04/30/81
	H	4	4	1	4	2	0	9	11/08/83	Cook et al.	424	243	06/13/77
V	I	4	5	2	2	8	1	1	06/11/85	Eppstein et al.	514	2	07/08/82

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
/EGS/	J	0	1	3	2	7	1	1	A2 05/10/01	PCT				
	K	0	1	4	4	8	0	9	A2 06/21/01	PCT				
	L	0	1	8	6	2	9	1	A1 11/15/01	PCT				
	M	03	0	2	3	0	3	2	A2 03/20/03	PCT				
	N	03	0	1	8	8	2	0	A2 03/06/03	PCT				
V	O	2	8	0	2	6	4	5	A1 06/22/01	FR				X+

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.  
37851-922SERIAL NO.  
10/658,834CONFIRM NO.  
7681APPLICANT  
GANTIER et al.CUSTOMER NO.  
24961FILING DATE  
September 8, 2003GROUP  
1644

OFFICE OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT



If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
/EGS/	P	2	8	0	8	8	0	4	A1 11/16/01	FR			X+

X+ = An English Language Equivalent is provided.

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/EGS/	Q	Bellido <i>et al.</i> , "The phospholipid and fatty acid composition of skeletal muscle cells during culture in the presence of vitamin D-3 metabolites," <i>Biochim Biophys Acta</i> , <u>922(2)</u> :162-169 (1987)
	R	Biron <i>et al.</i> , "Natural Killer Cells In Antiviral Defenses: Function and Regulation by Innate Cytokines," <i>Annu. Rev. Immunol.</i> , <u>17</u> :189-220 (1999)
	S	Boger <i>et al.</i> , "Surface Probability Profiles. A Heuristic Approach to the Selection of Synthetic Peptide Antigens," <i>Reports of the Sixth International Congress in Immunology</i> , p. 250 (1986)
	T	Briand <i>et al.</i> , "Impact of the lysine-188 and aspartic acid-189 inversion on activity of trypsin," <i>FEBS Lett.</i> , <u>442(1)</u> :43-47 (1999)
	U	Dayhoff <i>et al.</i> , "A Model of Evolutionary Change in Proteins," <i>Atlas of Protein Sequence and Structure</i> , <u>5(3)</u> :345-352 (1978)
	V	Diaz <i>et al.</i> , "Nomenclature of the Human Interferon Genes," <i>J. Interferon Cytokine Res.</i> , <u>16</u> :179-180 (1996)
	W	Drittanti <i>et al.</i> , "Effects of 1,25-dihydroxyvitamin D-3 on phospholipid metabolism in chick myoblasts," <i>Biochim Biophys Acta.</i> , <u>962(1)</u> :1-7 (1988)
↓	X	Drittanti <i>et al.</i> , "Changes in muscle lipid metabolism induced in vitro by 1,25-dihydroxy-vitamin D-3," <i>Biochim Biophys Acta</i> , <u>918(1)</u> :83-92 (1987)

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.  
37851-922SERIAL NO.  
10/658,834CONFIRM NO.  
7681APPLICANT  
GANTIER et al.CUSTOMER NO.  
24961FILING DATE  
September 8, 2003GROUP  
1644

# OFFICE OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/EGS/	Y	Drittanti <i>et al.</i> , "Involvement of the 3',5'-cyclic AMP pathway in the induction of calmodulin synthesis in myoblasts by 1,25(OH)2-vitamin D3," <i>Biochim Biophys Res Commun.</i> , <u>192(2)</u> :886-892 (1993)
	Z	Drittanti <i>et al.</i> , "Modulation of DNA synthesis in cultured muscle cells by 1,25-dihydroxyvitamin D-3," <i>Biochim Biophys Acta.</i> , <u>1014(2)</u> :112-119 (1989)
	AA	Drittanti <i>et al.</i> , "Stimulation of calmodulin synthesis in proliferating myoblasts by 1,25-dihydroxy-vitamin D3," <i>Mol Cell Endocrinol.</i> , <u>74(2)</u> :143-153 (1990)
	AB	Drittanti <i>et al.</i> , "Optimised helper virus-free production of high-quality adeno-associated virus vectors," <i>J Gene Med.</i> , <u>3(1)</u> :59-71 (2001)
	AC	Drittanti <i>et al.</i> , "Cystic fibrosis: gene therapy or preventive gene transfer?" <i>Gene Ther.</i> , <u>4(10)</u> :1001-1003 (1997)
	AD	Drittanti <i>et al.</i> , "High throughput production, screening and analysis of adeno-associated viral vectors," <i>Gene Ther.</i> , <u>7(11)</u> :924-929 (2000)
	AE	Du <i>et al.</i> , "Efficient transduction of human neurons with an adeno-associated virus vector," <i>Gene Ther</i> 3:254-261 (1996)
	AF	Feng <i>et al.</i> , Aligning Amino Acid Sequences: Comparison of Commonly Used Methods," <i>J. Mol. Evol.</i> , <u>21</u> :112-125 (1985)
	AG	Fitch, "An Improved Method of Testing for Evolutionary Homology," <i>J. Mol. Evol.</i> , <u>16(1)</u> :9-16 (1966)
	AH	Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Current Opinion in Structural Biology</i> , <u>6</u> :377-385 (1995)
	AI	Gonnet <i>et al.</i> , "Exhaustive Matching of the Entire Protein Sequence Database," <i>Science</i> , <u>256</u> :1433-1445 (1992)
↓	AJ	Grantham, "Amino Acid Difference Formula to Help Explain Protein Evolution," <i>Science</i> , <u>185</u> :862-864 (1974)

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

ATTY. DOCKET NO.  
37851-922SERIAL NO.  
10/658,834CONFIRM NO.  
7681APPLICANT  
GANTIER et al.CUSTOMER NO.  
24961FILING DATE  
September 8, 2003GROUP  
1644

# OFFICE OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/EGS/	AK	Grantier <i>et al.</i> , "The L392V mutation of presenilin 1 associated with autosomal dominant early-onset Alzheimer's disease alters the secondary structure of the hydrophilic loop," <i>Neuroreport</i> , <u>10(14)</u> :3071-3074 (1999)
	AL	Grantier <i>et al.</i> , "The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta," <i>Neurosci Lett.</i> , <u>283(3)</u> :217-220 (2000)
	AM	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction," <i>J Clin Invest.</i> , <u>94(1)</u> :16-24 (1994)
	AN	Guyon <i>et al.</i> , "Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss," <i>J Clin Invest.</i> , <u>102(1)</u> :249-263 (1998)
	AO	Henikoff <i>et al.</i> , "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad. Sci. USA</i> , <u>89</u> :10915-10919 (1992)
	AP	Hibbert <i>et al.</i> , "Human Type 1 Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells," <i>J. Interferon Cytokine Res.</i> , <u>19</u> :309-318 (1999)
	AQ	Hoedemaekers <i>et al.</i> , "Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis," <i>Ann N Y Acad Sci.</i> , <u>841</u> :550-554 (1998)
	AR	Hoedemaekers <i>et al.</i> , "Role of target organ in determining susceptibility to experimental autoimmune myasthenia gravis," <i>J Neuroimmunol.</i> , <u>89(1-2)</u> :131-141 (1998)
	AS	Holm <i>et al.</i> , "Mapping the Protein Universe," <i>Science</i> , <u>273</u> :595-602 (1996)
	AT	IUPAC-IUB "Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids)," <i>Biochem.</i> , <u>11</u> :942-944 (1972)
↓	AU	IUPAC-IUB "Commission on Biochemical Nomenclature A One-Letter Notation for Amino Acid Sequences Tentative Rules", <i>J. Biol. Chem.</i> , <u>243(13)</u> :3557-3559 (1968)

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

SERIAL NO.  
10/658.834

CONFIRM NO.  
7681

APPLICANT  
GANTIER et al.

**CUSTOMER NO.**  
**24961**

**FILING DATE**  
September 8, 2003

**GROUP  
1644**

# LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO on a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

## /EGS/

AV

Johnson *et al.*, "A Structural Basis for Sequence Comparisons. An Evaluation of Scoring Methodologies," *J. Mol. Biol.*, 233:716-738 (1993)

**AW**

Jones *et al.*, "The rapid generation of mutation data matrices from protein sequences," *Comput. Appl. Biosci.*, 8:275-282 (1992)

**AX**

Lu, G., "TOP: a new method for protein structure comparisons and similarity searches," *J. Appl. Cryst.*, 33:176-189 (2000)

AY

Marrack *et al.*, "Type I Interferons Keep Activated T Cells Alive," *J. Exp. Med.*, 189:521-530 (1999)

AZ

Masciovecchio *et al.*, "The interactivity between the CFTR gene and cystic fibrosis" would be limited to the initial phase of the disease," *Genet Med.*, 2(2):124-130 (2000)

BA

McLachlan, "Tests for Comparing Related Amino-acid Sequences. Cytochrome c and Cytochrome  $c_{551}$ ," *J. Mol. Biol.*, 61:409-424 (1971)

BB

Miyata, "Two Types of Amino Acid Substitutions in Protein Evolution," *J. Mol. Evol.*, 12:219-236 (1979)

BC

Morikawa *et al.*, "Recombinant interferon- $\alpha$ , - $\beta$  and - $\gamma$  enhance the proliferative response of human B cells," *J. Immunol.*, 139:761-766 (1987)

BD

Moulian *et al.*, "Respective role of thymus and muscle in autoimmune myasthenia gravis," *Ann N Y Acad Sci.*, 841:397-406 (1998)

BE

Murzin *et al.*, "SCOP: A Structural Classification of Proteins Database for the Investigation of Sequences and Structures," *J. Mol. Biol.*, **247**:536-540 (1995)

**BF**

Orengo *et al.*, "CATH - a hierarchic classification of protein domain structures," *Structure*, 5(8):1093-1108 (1997)

**BG**

Pestka *et al.*, "Interferons and Their Actions," *Annu. Rev. Biochem.*, **56**:727-777 (1987)

**EXAMINER**

**/Elly Gerald Stoica/**

DATE CONSIDERED

03/15/2007

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Title: RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 37851-922	SERIAL NO. 10/658,834	CONFIRM NO. 7681
	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644	

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


/EGS/	BH	Piehler <i>et al.</i> , "New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface," <i>J. Biol. Chem.</i> , <u>275</u> :40425-40433 (2000)
	BI	Poea <i>et al.</i> , "Modulation of acetylcholine receptor expression in seronegative myasthenia gravis," <i>Ann Neurol.</i> , <u>48</u> (5):696-705 (2000)
	BJ	Poëa <i>et al.</i> , "Expression of ciliary neurotrophic factor receptor in myasthenia gravis," <i>J Neuroimmunol.</i> , <u>120</u> (1-2):180-189 (2001)
	BK	Rao, "New scoring matrix for amino acid residue exchanges based on residue characteristic physical parameters," <i>J. Pept. Protein Res.</i> , <u>29</u> :276-281 (1987)
	BL	Raux <i>et al.</i> , "The -2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit," <i>Mol Psychiatry</i> , <u>7</u> (9):1006-1011 (2002)
	BM	Raux <i>et al.</i> , "A novel presenilin 1 missense mutation (L153V) segregating with early-onset autosomal dominant Alzheimer's disease," <i>Human Mutat.</i> , Report #134, two pages (2000)
	BN	Raux <i>et al.</i> , "Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation," <i>Neurol.</i> , <u>55</u> (10):1577-1578 (2000)
	BO	Risler <i>et al.</i> , "Amino Acid Substitutions in Structurally Related Proteins A Pattern Recognition Approach," <i>J. Mol. Biol.</i> , <u>204</u> :1019-1029 (1988)
	BP	Robert <i>et al.</i> , "Interferon Induces Proliferation In Leukemic And Normal B-Cell Subsets," <i>Hematol. Oncol.</i> , <u>4</u> :113-120 (1986)
	BQ	Roisman <i>et al.</i> , "Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking," <i>Proc. Natl. Acad. Sci. USA</i> , <u>98</u> :13231-13236 (2001)
↓	BR	Sali <i>et al.</i> , "Definition of General Topological Equivalence in Protein Structures," <i>J. Mol. Biol.</i> , <u>212</u> :403-428 (1990)

EXAMINER /Elly Gerald Stoica/

DATE CONSIDERED 03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449  LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 37851-922	SERIAL NO. 10/658,834	CONFIRM NO. 7681
	APPLICANT GANTIER et al.	CUSTOMER NO. 24961	
	FILING DATE September 8, 2003	GROUP 1644	

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/EGS/	BS	Sanchez <i>et al.</i> , "Spastic paraplegia and primary adrenal insufficiency: a case of adrenomyeloneuropathy," <i>Medicina (B Aires)</i> , <u>48(3)</u> :290-296 (1988) (Summary in English)
	BT	Scheel-Toeller <i>et al.</i> , "Inhibition of T cell apoptosis by IFN- $\beta$ rapidly reverses nuclear translocation of protein kinase C- $\delta$ ," <i>Eur. J. Immunol.</i> , <u>29</u> :2603-2612 (1999)
	BU	Shindyalov <i>et al.</i> , "Protein structure alignment by incremental combinatorial extension (CE) of the optimal path," <i>Protein Engineering</i> , <u>11(9)</u> :739-747 (1998)
	BV	Smith <i>et al.</i> , "Single-step purification of polypeptides expressed in <i>Escherichia coli</i> as fusions with glutathione S-transferase," <i>Gene</i> , <u>67</u> :31-40 (1988)
	BW	Stark <i>et al.</i> , "How cells Respond to Interferons," <i>Annu. Rev. Biochem.</i> , <u>67</u> :227-264 (1998)
↓	BX	Wakkach <i>et al.</i> , "Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis," <i>J Immunol.</i> , <u>157(8)</u> :3752-3760 (1996)

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**

FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
37851-922

SERIAL NO.  
10/658,834

CONFIRM NO.  
7681

APPLICANT  
GANTIER et al.

CUSTOMER NO.  
24961

FILING DATE  
September 8, 2003

GROUP  
1644

\* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

\*\* If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

+ Derwent English language abstract and/or English translation provided.

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
/EGS/	A	0	1	7	5	6	9	4	09/18/03	Vega	435	5	05/04/01

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
/EGS/	B	0	1	8	6	2	9	1	11/15/01	PCT			+	
/EGS/	C	1	0	2	2	3	3	5	07/26/00	EP				
/EGS/	D	9	7	3	8	7	2	3	10/23/97	PCT				
/EGS/	E	9	8	3	2	8	8	0	07/30/98	PCT				

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	NONE
--	------

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **RATIONAL EVOLUTION OF CYTOKINES FOR HIGHER STABILITY, THE CYTOKINES AND ENCODING NUCLEIC ACID MOLECULES**



Substitute Form PTO-1449 (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office NOV 09 2004	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
	Applicant Rene Gantier et al.		
	Filing Date September 8, 2003	Group Art Unit 1646	

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	3,171,820	03/02/65	Volz et al.	521	61	02/17/64
/EGS/	AB	5,223,409	06/29/93	Ladner et al.	435	69.7	03/01/91
/EGS/	AC	6,013,478	01/11/00	Wells et al.	435	69.1	06/24/98
/EGS/	AD	6,171,820	01/09/01	Short	435	69.1	02/04/99
/EGS/	AE	2003/0224404	12/04/03	Vega et al.	435	6	02/24/03

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/EGS/	AF	01/61344	08/23/01	PCT				
/EGS/	AG	01/025438	04/12/01	PCT				
/EGS/	AH	04/022747	03/18/04	PCT				
/EGS/	AI	04/022593	03/18/04	PCT				
/EGS/	AJ	0 240 224	10/07/87	EP				

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/EGS/	AK	Kuhn "Structural basis for the positional specificity of lipoxygenases" Prostaglandins and other lipid mediators 62(3): 255-270 (2000)
/EGS/	AL	Lewerenz et al. "Shared receptor components but distinct complexes for alpha and beta interferons" J. Mol. Biol. 282(3): 585-599 (1998)
/EGS/	AM	Manetti et al. "Design and realization of a tailor-made enzyme to modify the molecular recognition of 2-arylpropionic esters by Candida rugosa lipase" Biochem. Biophys. Acta 1543(1): 146-158 (2000)

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Rene Gantier, et al.	
		Filing Date September 8, 2003	Group Art Unit 1646

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	4797368	01/10/89	Carter et al.	435	320	03/15/85
	AB	5139941	08/18/92	Muzyczka et al.	435	172.3	10/25/91
	AC	5571698	11/05/96	Ladner et al.	435	69.7	06/18/93
	AD	5723323	03/03/98	Kauffman et al.	435	172.3	12/02/94
	AE	5753500	05/19/98	Shenk et al.	435	320.1	04/03/95
	AF	5763239	06/09/98	Short et al.	435	172.1	06/18/96
	AG	5770434	06/23/98	Huse	435	252.33	05/15/95
	AH	5779434	07/14/98	De Long	415	104	02/06/97
	AI	5798208	08/25/98	Crea	435	6	11/02/92
	AJ	5798390	08/25/98	Weber et al.	514	634	05/22/95
	AK	5837500	11/17/98	Ladner et al.	435	69.7	04/03/95
	AL	5862514	01/19/99	Huse et al.	702	22	12/06/96
	AM	5871974	02/16/99	Huse	435	69.7	12/02/94
	AN	6001574	12/14/99	Short et al.	435	6	03/04/98
	AO	6057103	05/02/00	Short	435	6	08/26/97
	AP	6096548	08/01/00	Stemmer	435	440	02/03/97
	AQ	6117679	09/12/00	Stemmer	435	440	05/25/96
	AR	6127175	10/03/00	Vigne et al.	435	325	07/17/97
	AS	6132970	10/17/00	Stemmer	435	6	06/19/98
	AT	6156509	12/05/00	Schellenberger	435	6	11/12/97
	AU	6165793	12/26/00	Stemmer	435	440	05/08/98
	AV	6174673	01/16/01	Short et al.	435	6	06/16/98
	AW	6180406	01/30/01	Stemmer	435	440	06/17/98
	AX	6238884	05/29/01	Short et al.	435	69.1	03/09/99
	AY	6258530	07/10/01	Huse	435	6	12/30/94

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner	Desig.	Document	Publication	Country or	Class	Subclass	Translation
Examiner Signature /Elly Gerald Stoica/				Date Considered 03/15/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922		Application No. 10/658,834	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Rene Gantier, et al.			
				Filing Date September 8, 2003		Group Art Unit 1646	
						Yes	No
/EGS/	AZ	02/16606	02/28/02	PCT		X	
/EGS/	BA	99/64582	12/16/99	PCT			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/EGS/	BB	Altschul et al., "Basic Local Alignment Search Tool", J. Molec. Biol., 215:403-410 (1990)
	BC	Ashktorab et al., "Identification of Nuclear Proteins That Specifically Interact with Adeno-Associated Virus Type 2 Inverted Terminal Repeat Hairpin DNA", Journal of Virology, 63:3034-3039 (1989)
	BD	ATCC accession no. VR-1449, "Simian virus 15", (accessed on 09/05/2002)
	BE	ATCC accession no. VR-645, "Adeno-associated virus 1 deposited as Adeno-associated (satellite) virus type 1", (accessed on 09/05/2002)
	BF	ATCC accession no. VR-646, "Adeno-associated virus 4 deposited as Adeno-associated virus type 4", (accessed on 09/05/2002)
	BG	ATCC accession no. VR-680, "Adeno-associated virus 2 deposited as Adeno-associated virus type 2", (accessed on 09/05/2002)
	BH	ATCC accession no. VR-681, "Adeno-associated virus 3 deposited as Adeno-associated virus type 3", (accessed on 09/05/2002)
	BI	Atkinson et al., "A high-throughput hybridization method for titer determination of viruses and gene therapy vectors", Nucleic Acids Research., 26:2821-2823 (1998)
	BJ	Batchu et al., "Disassociation of Conventional DNA Binding and Endonuclease Activities by an Adeno-Associated Virus Rep78 Mutant", Biochemical And Biophysical Research Communications, 210:717-725 (1995)
	BK	Beaton et al., "Expression from the Adeno-Associated Virus p5 and p19 Promoters Is Negatively Regulated in trans by the rep Protein", Journal of Virology, 63:4450-4454 (1989)
	BL	Beck-Sickinger et al., "Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations", Eur. J. Biochem., 223:947-958 (1994)
	BM	Carrillo et al., "The Multiple Sequence Alignment Problem in Biology", SIAM J. Applied Math, 48:1073-1082 (1988)
	BN	Cassinotti et al., "Organization of the Adeno-Associated Virus (AAV) Capsid Gene: Mapping of a Minor Spliced mRNA Coding for Virus Capsid Protein 1", Virology, 167:176-184 (1988)
	BO	Certified English Translation of PCT Patent Application No. WO 01/44809, "Methods for Screening or Assessing the Performance of a Collection of Biological Agents in Living Target Cells, and their Applications."
	BP	Certified English Translation of PCT Patent Application No. WO 01/86291, "Method for Determining the Titer of Biological Agents in Living Target Cells."
	BQ	Certified English Translation of PCT Patent Application No. WO 02/16606, "Method for Massive Directed Mutagenesis."
↓	BR	Chadeuf et al., "Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome", J. Gene Med., 2:260-268 (2000)

Examiner Signature  /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922		Application No. 10/658,834	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Rene Gantier, et al.			
				Filing Date September 8, 2003		Group Art Unit 1646	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/EGS/-	BS	Charbord <i>et al.</i> "Normal human granulo monocytic bone marrow progenitor cells responsiveness to colony stimulating activity" <i>Nouv. Rev. Fr. Hematol.</i> 22: 357-370, (1980)					
	BT	Chejanovsky <i>et al.</i> , "Mutagenesis of an AUG Codon in the Adeno-Associated Virus rep Gene: Effects on Viral DNA Replication", <i>J. Virology</i> , 173:120-128 (1989)					
	BU	Chejanovsky <i>et al.</i> , "Mutation of a Consensus Purine Nucleotide Binding Site in the Adeno-Associated Virus rep Gene Generates a Dominant Negative Phenotype for DNA Replication", <i>J. Virology</i> , 64:1764-1770 (1990)					
	BV	Cullen <i>et al.</i> , "Analysis of the Physical State of Different Human Papillomavirus DNAs in Intraepithelial and Invasive Cervical Neoplasm", <i>Journal of Virology</i> , 65:606-612 (1991)					
	BW	Davis <i>et al.</i> "High throughput method for creating and screening recombinant adenoviruses" <i>Gene Therapy</i> 5(8) pp1148-1152 (1998)					
	BX	Davis <i>et al.</i> , "Analysis of the Effects of Charge Cluster Mutations in Adeno-Associated Virus Rep68 Protein In Vitro", <i>Journal of Virology</i> , 73:2084-2093 (1999)					
	BY	Davis <i>et al.</i> , "Mutational Analysis of Adeno-Associated Virus Type 2 Rep68 Protein Endonuclease Activity on Partially Single-Stranded Substrates", <i>Journal of Virology</i> , 74:2936-2942 (2000)					
	BZ	Deng <i>et al.</i> , "Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site", <i>Analytical Biochemistry</i> , 200:81-88 (1992)					
	CA	Derwent # 013914049, WPI Acc. No. 2001-398262/200142, for French Patent FR 2802645 and PCT Patent Application WO 2001/44809 "Evaluating the performance of complex biological agents in target cells, for selecting gene therapy vectors with optimal properties, comprises constructing a theoretical curve"					
	CB	Devereux <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX", <i>Nucleic Acids Research</i> , 12(I):387-395 (1984)					
	CC	Gavin <i>et al.</i> , "Charge-to-Alanine Mutagenesis of the Adeno-Associated Virus Type 2 Rep78/68 Proteins Yields Temperature-Sensitive and Magnesium-Dependent Variants", <i>Journal of Virology</i> , 73:9433-9445 (1999)					
	CD	Genbank accession no. NC_001401, Nucleotide, "Adeno-associated virus 2, complete genome", (accessed on 09/05/02)					
	CE	Genbank accession no. NC_001729, Nucleotide, "Adeno-associated virus 3, complete genome", (accessed on 09/05/02)					
	CF	Genbank accession no. NC_001829, Nucleotide, "Adeno-associated virus 4, complete genome", (accessed on 09/05/2002)					
	CG	Genbank accession no. NC_001863, Nucleotide, "Adeno-associated virus 3B, complete genome", (accessed on 09/05/2002)					
	CH	Genbank accession no. NC_002077, Nucleotide, "Adeno-associated virus 1, complete genome", (accessed on 09/05/2002)					
	CI	Gibbs <i>et al.</i> , "Rational Scanning Mutagenesis of a Protein Kinase Identifies Functional Regions Involved in Catalysis and Substrate Interactions", <i>Journal of Biology Chemistry</i> , 266:8923-8931 (1991)					
	CJ	Gribskov <i>et al.</i> , "Sigma factors from <i>E. coli</i> , <i>B. subtilis</i> , phage SP01, and phage T4 are homologous proteins", <i>Nucleic Acids Research</i> , 14:6745-6763 (1986)					
↓	CK	Hermonat <i>et al.</i> , "Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants", <i>Journal of Virology</i> , 51:329-339 (1984)					
Examiner Signature /Elly Gerald Stoica/				Date Considered 03/15/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922		Application No. 10/658,834	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Rene Gantier, et al.			
				Filing Date September 8, 2003		Group Art Unit 1646	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/EGS/	CL	Hermonat, P.L., "Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78", <i>Cancer Letters</i> , 81:129-136 (1994)					
	CM	Hill A.V., "The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves", <i>Proceedings of the Physiological, Journal of Physiology</i> , 40:iv-vii (1910)					
	CN	Hill et al., "XLVII. The Combinations Of Haemoglobin With Oxygen And With Carbon Monoxide", <i>I. Biochem. J.</i> , 7:471-480 (1913)					
	CO	Horer et al., "Mutational Analysis of Adeno-Associated Virus Rep Protein-Mediated Inhibition of Heterologous and Homologous Promoters", <i>Journal of Virology</i> , 69:5485-5496 (1995)					
	CP	Im et al., "Partial Purification of Adeno-Associated Virus Rep78, Rep52, and Rep40 and Their Biochemical Characterization", <i>Journal of Virology</i> , 66:1119-1128 (1992)					
	CQ	Im et al., "The AAV Origin Binding Protein Rep68 Is an ATP-Dependent Site-Specific Endonuclease with DNA Helicase Activity", <i>Cell</i> , 61:447-457 (1990)					
	CR	Kechli et al., "Expression of the Human Immunodeficiency Virus Type 1 Primer Binding Sequence Inhibits HIV-1 Replication", <i>Human Gene Therapy</i> , 9:587-590 (1998)					
	CS	Kyostio et al., "Analysis of Adeno-Associated Virus (AAV) Wild-Type and Mutant Rep Proteins for Their Abilities To Negatively Regulate AAV p5 and p19 mRNA Levels", <i>Journal of Virology</i> , 68:2947-2957 (1994)					
	CT	Kyostio et al., "Identification of Mutant Adeno-Associated Virus Rep Proteins Which Are Dominant-Negative For DNA Helicase Activity", <i>Biochemical and Biophysical Research Communications</i> , 220:294-299 (1996)					
	CU	Kyostio et al., "Negative Regulation of the Adeno-Associated Virus (AAV) P5 Promoter Involves both the P5 Rep Binding Site and the Consensus ATP-Binding Motif of the AAV Rep68 Protein", <i>Journal of Virology</i> , 69:6787-6796 (1995)					
	CV	Marcello et al., "Adeno-Associated Virus Type 2 Rep Protein Inhibits Human Papillomavirus Type 16 E2 Recruitment of the Transcriptional Coactivator p300", <i>Journal of Virology</i> , 74:9090-9098 (2000)					
	CW	Matsushita et al., "Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin by Charged-to-Alanine Scanning Mutagenesis", <i>Journal of Biology Chemistry</i> , 275:11044-11049 (2000)					
	CX	McCarty et al., "Analysis of Mutations in Adeno-Associated Virus Rep Protein In Vivo and In Vitro", <i>Journal of Virology</i> , 66:4050-4057 (1992)					
	CY	Mendelson et al., "Identification of the trans-Acting Rep Proteins of Adeno-Associated Virus by Antibodies to a Synthetic Oligopeptide", <i>Journal of Virology</i> , 60:823-832 (1986)					
	CZ	Mittereder et al., "Evaluation of the Concentration and Bioactivity of Adenovirus Vectors for Gene Therapy", <i>Journal of Virology</i> , 70:7498-7509 (1996)					
	DA	Moullier et al., "Comparative binding of wheat germ agglutinin and its succinylated form on lymphocytes" <i>European J. Biochem.</i> 161: 197-204 (1986)					
	DB	Needleman et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", <i>Journal of Molecular Biology</i> , 48:443-453 (1970)					
	DC	Nelson et al., "Characterization of Diverse Viral Vector Preparations, Using a Sample and Rapid Whole-Virion Dot-Blot Method", <i>Hum. Gene Ther.</i> , 9:2401-2405 (1998)					
	DD	Ni et al., "In Vitro Replication of Adeno-Associated Virus DNA", <i>Journal of Virology</i> , 68:1128-1138 (1994)					
Examiner Signature /Elly Gerald Stoica/				Date Considered 03/15/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))			Applicant R��ne Gantier, et al.	
			Filing Date September 8, 2003	Group Art Unit 1646
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
/EGS/	DE	Owens et al., "Adeno-Associated Virus Rep Proteins Produced in Insect and Mammalian Expression Systems: Wild-Type and Dominant-Negative Mutant Proteins Bind to the Viral Replication Origin", <i>Journal of Virology</i> , 184:14-22 (1991)		
	DF	Owens et al., "Identification of a DNA-Binding Domain in the Amino Terminus of Adeno-Associated Virus Rep Proteins," <i>J. Virology</i> , 67(2):997-1005 (1993)		
	DG	Owens et al., "In Vitro Resolution of Adeno-Associated Virus DNA Hairpin Termini by Wild-Type Rep Protein Is Inhibited by a Dominant-Negative Mutant of Rep", <i>Journal of Virology</i> , 66:1236-1240 (1992)		
	DH	Pearson et al., "Improved tools for biological sequence comparison", <i>Proc. Natl. Acad. Sci. USA</i> , 85:2444-2448 (1988)		
	DI	Press Release 10; "Nautilus Biotech and Microbix Biosystems, Inc. (TSE: MBX) sign a distribution agreement for rAAV high-producer cells"; Paris- January 11, 2002; <a href="http://www.nautilusbiotech.com/news-pressrelease10.php3">http://www.nautilusbiotech.com/news-pressrelease10.php3</a> , accessed on (2/28/02)		
	DJ	Press Release 11; "Nautilus Biotech granted patent covering molecular fitness analysis with key applications in directed evolution and functional genomics target identification"; Paris- February 6, 2002; <a href="http://www.nautilusbiotech.com/news-pressrelease11.php3">http://www.nautilusbiotech.com/news-pressrelease11.php3</a> , accessed on (2/28/02)		
	DK	Press Release 6; "Nautilus Biotech S.A. Files a Key Patent Application in the U.S."; Paris- September 14, 2001; <a href="http://www.nautilusbiotech.com/news-pressrelease6.php3">http://www.nautilusbiotech.com/news-pressrelease6.php3</a> , accessed on (2/28/02)		
	DL	Press Release 7; "Nautilus Biotech optimizes the AAV rep protein to increase rAAV productivity"; Paris- September 21, 2001; <a href="http://www.nautilusbiotech.com/news-pressrelease7.php3">http://www.nautilusbiotech.com/news-pressrelease7.php3</a> , accessed on (2/28/02)		
	DM	Ropp et al., "Aequorea Green Fluorescent Protein Analysis by Flow Cytometry", <i>Cytometry</i> , 21:309-317 (1995)		
	DN	Ruffing et al., "Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif", <i>J. Gen. Virol.</i> , 75:3385-3392 (1994)		
	DO	Ryan et al., "Sequence Requirements for Binding of Rep68 to the Adeno-Associated Virus Terminal Repeats", <i>Journal of Virology</i> , 70:1542-1553 (1996)		
	DP	Salveti et al., "Factors Influencing Recombinant Adeno-Associated Virus Production", <i>Hum. Gene Ther.</i> , 20:695-706 (1998)		
	DQ	Samulski et al., "A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its Use To Study Viral Replication", <i>Journal of Virology</i> , 61:3096-3101 (1987)		
	DR	Schumann <i>et al.</i> "Intracellular Ca <sup>2+</sup> inhibits smooth muscle L-type Ca <sup>2+</sup> channels by activation of protein phosphatase type 2B and by direct interaction with the channel", <i>J. General Physiology</i> 110: 503-513 (1997)		
	DS	Schwartz et al., "Matrices for Detecting Distant Relationships", <i>Atlas of Protein Sequence and Structure</i> , National Biomedical Research Foundation, pp. 353-358 (1978)		
	DT	Smith et al., "Comparison of Biosequences", <i>Advances in Applied Mathematics</i> , 2:482-489 (1981)		
↓	DU	Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome", <i>Journal of Virology</i> , 45:555-564 (1983)		

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17109-012001 / 922		Application No. 10/658,834	
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant R��ne Gantier, et al.			
				Filing Date September 8, 2003		Group Art Unit 1646	
Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document					
/EGS/	DV	Tessier et al., "Characterization of Adenovirus-Induced Inverted Terminal Repeat-Independent Amplification of Integrated Adeno-Associated Virus rep-cap Sequences", Journal of Virology, 75:375-383 (2001)					
	DW	Urabe et al., "Charged-to-Alanine Scanning Mutagenesis of the N-Terminal Half of Adeno-Associated Virus Type 2 Rep78 Protein", Journal of Virology, 23:2682-2693 (1999)					
	DX	Walker et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 Rep68 Protein Helicase Motifs", Journal of Virology, 71:6996-7004 (1997)					
	DY	Walker et al., "Mutational Analysis of the Adeno-Associated Virus Rep68 Protein: Identification of Critical Residues Necessary for Site-Specific Endonuclease Activity", Journal of Virology, 71:2722-2730 (1997)					
	DZ	Watson et al., "Molecular Biology of the Gene", 4th Ed., The Benjamin/Cummings Pub. Co., p. 224, (1987)					
	EA	Weitzman et al., "Interaction of Wild-Type and Mutant Adeno-Associated Virus (AAV) Rep Proteins on AAV Hairpin DNA", Journal of Virology, 70:2240-2248 (1996)					
	EB	Weitzman et al., "Recruitment of Wild-Type and Recombinant Adeno-Associated Virus into Adenovirus Replication Centers", Journal of Virology, 70:1845-1854 (1996)					
	EC	Wu et al., "Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism", J. Virol., 74:8635-8647 (2000)					
	ED	Xiao et al., "Construction and Screening of a Multi-Point Site-Specific Mutant Library of Subtilisin E with a Set of Oligonucleotides", Science in China (Series C) 40(4):337-344 (1997)					
	EE	Yang et al., "Analysis of the Terminal Repeat Binding Abilities of Mutant Adeno-Associated Virus Replication Proteins", Journal of Virology, 67: 4442-4447 (1993)					
	EF	Yang et al., "Mutational Analysis of the Adeno-Associated Virus rep Gene", Journal of Virology, 66:6058-6069 (1992)					
	EG	Yoon et al., "Amino-Terminal Domain Exchange Redirects Origin-Specific Interactions of Adeno-Associated Virus Rep78 In Vitro", Journal of Virology, 75:3230-3239 (2001)					

Examiner Signature  /Elly Gerald Stoica/	Date Considered  03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
17109-012001 / 922Application No.  
10/658,834List of Patents and Publications for Applicant's  
Information Disclosure StatementApplicant  
Rene Gantier et al.Filing Date  
September 8, 2003Group Art Unit  
1646

(37 CFR § 1.98(b))

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
		none					

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/EGS/	AA	01/25253	04/12/01	PCT				
	AB	01/32844	05/10/01	PCT				
	AC	95/23813	09/08/95	PCT				
	AD	98/13487	04/02/98	PCT				
	AE	99/07833	02/18/99	PCT				
V	AF	99/11764	03/11/99	PCT				

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
		none

Examiner Signature

/Elly Gerald Stoica/

Date Considered

03/15/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
	Applicant Rene Gantier et al.		
	Filing Date September 8, 2003	Group Art Unit 1646	

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	5017371	05/21/91	Cummins	424	85.6	01/06/88
/EGS/	AB	5215741	06/01/93	Young et al.	424	85.7	10/30/90
/EGS/	AC	6036949	03/14/00	Richards et al.	424	85.7	03/05/98
/EGS/	AD	6506377	01/14/03	Cummins et al.	424	85.7	09/27/01

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/EGS/	AE	Kim, S. and H. Moon, "Purification and Characterization of Intracellular and Extracellular Inulase from <i>Kluyveromyces marxianus</i> ," <i>Journal of the Korean Agricultural Chemical Society</i> 30(2): 169-178 (June, 1987)

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
	Applicant Rene Gantier et al.		
	Filing Date September 8, 2003	Group Art Unit 1646	

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	20020081574	6/27/2002	Collett et al.			
/EGS/	AB	20050202438	9/15/05	Gantier et al.			
/EGS/	AC	5925565	7/20/1999	Berlioz et al.			


**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
		none

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001 / 922	Application No. 10/658,834
		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

**List of Patents and Publications for Applicant's  
Information Disclosure Statement**

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	2006-0020116	01/26/06	Gantier et al.			
/EGS/	AB	2006-0020396	01/26/06	Gantier et al.			
/EGS/	AC	2006-0094655	05/04/06	Guyon et al.			
/EGS/	AD	5,096,815	03/17/92	Ladner et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
		none						

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/EGS/	AE	Alam et al., "Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro," Journal of Biotechnology 65: 183-190 (1998)
/EGS/	AF	Chiang et al., "In vivo genetic analysis of bacterial virulence," Annu. Rev. Microbiol. 53: 129-154 (1999)
/EGS/	AG	Zlauddin et al., "Microarrays of cells expressing defined cDNAs," Nature 411: 107-110 (2001)

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

<b>Substitute Form PTO-1449</b> (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Attorney's Docket No.</b> 17109-012001 / 922	<b>Application No.</b> 10/658,834
	<b>Applicant</b> Rene Gantier et al.		
	<b>Filing Date</b> September 8, 2003		<b>Group Art Unit</b> 1631

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	none					

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	none						

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/EGS/	AC	Giver <i>et al.</i> "Directed Evolution of a Thermostable Esterase," <i>PNAS</i> (1998) 95: 12809-12813
/EGS/	AD	Persson <i>et al.</i> "Virus-Receptor Interaction in the Adenovirus System: Characterization of the Positive Cooperative Binding of Virions on HeLa Cells," <i>Journal of Virology</i> (1985) 54: 92-97

<b>Examiner Signature</b> /Elly Gerald Stoica/	<b>Date Considered</b> 03/15/2007
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 4

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001/922	Application No. 10/658,834
		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/EGS/	AA	2004/0002474	1/1/2004	Heinrichs <i>et al.</i>			
	AB	2004/0082026	4/29/2004	DeFrees <i>et al.</i>			
	AC	2004/0219131	11/4/2004	Patten <i>et al.</i>			
	AD	2004/0230040	11/18/2004	Cox, George N.			
	AE	2005/0019871	1/27/2005	Lee <i>et al.</i>			
	AF	2005/0026834	2/3/2005	Cox <i>et al.</i>			
	AG	2005/0058621	3/17/2005	Cox, George N.			
	AH	4,503,035	3/5/1985	Pestka <i>et al.</i>			
	AI	4,678,751	7/7/1987	Goeddel, David V.			
	AJ	4,820,638	4/11/1989	Swetly <i>et al.</i>			
	AK	5,198,345	3/30/1993	Gwynne <i>et al.</i>			
	AL	5,441,734	8/15/1995	Reichert <i>et al.</i>			
	AM	5,460,956	10/24/1995	Reichert <i>et al.</i>			
	AN	5,602,232	2/11/1997	Reichert <i>et al.</i>			
	AO	5,710,027	1/20/1998	Hauptmann <i>et al.</i>			
	AP	6,165,458	12/26/2000	Foldvari <i>et al.</i>			
	AQ	6,204,022	3/20/2001	Johnson <i>et al.</i>			
	AR	6,299,870	10/9/2001	Pestka, Sidney			
	AS	6,300,474	10/9/2001	Pestka, Sidney			
	AT	6,372,218	4/16/2002	Cummins, Joseph M.			
	AU	6,455,253	9/24/2002	Patten <i>et al.</i>			
	AV	6,608,183	8/19/2003	Cox III, George N.			
	AW	6,610,830	8/26/2003	Goeddel <i>et al.</i>			
	AX	6,815,184	11/9/2004	Stomp <i>et al.</i>			
	AY	6,846,844	11/27/2003	Tang, Pingwah			
	AZ	6,897,297	5/24/2005	Pepinsky <i>et al.</i>			

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001/922	Application No. 10/658,834
	Applicant Rene Gantier et al.		
	Filing Date September 8, 2003	Group Art Unit 1631	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/EGS/	BA	0 051 873 B1	9/27/1989	EP				
	BB	0 146 903 A2	7/3/1985	EP				
	BC	0 240 224 A2	10/7/1987	EP				
	BD	0 625 991 B1	4/28/1999	EP				
	BE	02/085941 A2	10/31/2002	PCT				
	BF	2004/019856 A2	3/11/2004	PCT				
	BG	2004/031352 A2	4/15/2004	PCT				
	BH	2004/074486 A2	9/2/2004	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/EGS/	BI	"Interferon Gamma: Amarillo Biosciences, Inc. and Hayashibara Biochemical Laboratories Broaden Scope of Interferon Gamma Agreement," PR News Wire, <a href="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&amp;STORY=/www/story/06-15-2000/0001244415&amp;EDATE=">http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&amp;STORY=/www/story/06-15-2000/0001244415&amp;EDATE=</a> (accessed on 10/18/2006), 2 pages.
	BJ	"Low Dose Oral Interferon Alpha- Our Lead Product Candidate," Amarillo Biosciences, <a href="http://www.amarbio.com/03productcandidate.html">http://www.amarbio.com/03productcandidate.html</a> (accessed on 10/18/2006), 2 pages.
	BK	"More Facts on Our Lead Product Candidate - Low Dose Oral Interferon Alpha," Amarillo Biosciences, <a href="http://www.amarbio.com/04.html">http://www.amarbio.com/04.html</a> (accessed on 10/18/2006), 2 pages.
	BL	"Amarillo Biosciences (AMAR) to Receive Patent on Solid Dosage Forms of Interferon; Company Also Obtains Private Funding Through Private Placement," PR News Wire, <a href="http://www.acor.org/drugs/pipeline/news/parsed/7795515.news">http://www.acor.org/drugs/pipeline/news/parsed/7795515.news</a> (accessed on 10/20/2006), 2 pages.
	BM	"LDO-IFNa Ingredients," <a href="http://www.angelfire.com/indie/bdchat/IFNaOfficialRpt.html">http://www.angelfire.com/indie/bdchat/IFNaOfficialRpt.html</a> (accessed on 3/30/2005), 1 page.
	BN	Adolf <i>et al.</i> , "Natural human interferon- $\alpha$ 2 is O-glycosylated," <i>Biochem J.</i> 276: 511-518 (1991)
	BO	Allen, G. and K.H. Fantes, "A family of structural genes for human lymphoblastoid (leukocyte-type) interferon," <i>Nature</i> 287: 408-11 (1980)
	BP	Balk <i>et al.</i> , "Biology of prostate-specific antigen," <i>J Clin Oncology</i> 21:383-391 (2003)
	BQ	Bielharz <i>et al.</i> , "Antiviral and Antiproliferative Activities of Interferon- $\alpha$ 1: The Role of Cysteine Residues," <i>J. Interferon Research</i> 6:677-685 (1986)
	BR	Brod, S.A., "Ingested type I interferon: state of the art as treatment for autoimmunity," <i>Exp Biol Med</i> 227(11):981-8 (2002)

Examiner Signature /Elly Gerald Stoical/	Date Considered 03/15/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001/922	Application No. 10/658,834
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/EGS/	BS	Brod <i>et al.</i> , "Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis," <i>J Neuroimmunol</i> 58(1):61-9 (1995)
	BT	Déry <i>et al.</i> , "Proteinase-activated receptors: novel mechanisms of signaling by serine proteases," <i>Am. J. Physiol</i> 274:C1429-C1452 (1998)
	BU	Di Marco <i>et al.</i> , "Mutational Analysis of the Structure-Function Relationship in Interferon- $\alpha$ ," <i>Biochem Biophys Res Comm</i> 202: 1445-1451 (1994)
	BV	Fink <i>et al.</i> , "Biological Characterization of Three Novel Variants of IFN- $\alpha$ 13 Produced by Human Placental Trophoblast," <i>Placenta</i> 22: 673-680 (2001)
	BW	Goeddel <i>et al.</i> , "Human leukocyte interferon produced by E. coli is biologically active," <i>Nature</i> 287: 411-416 (1980)
	BX	Hu <i>et al.</i> , "Human IFN- $\alpha$ Protein Engineering: The Amino Acid Residues at Positions 86 and 90 are Important for Antiproliferative Activity," <i>J. Immunol.</i> 167: 1482-1489 (2001)
	BY	Khurshudian, A.V., "A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome," <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod.</i> 95(1):38-44 (2003)
	BZ	Lawn <i>et al.</i> , "DNA sequence of a major human leukocyte interferon gene," <i>PNAS</i> 78: 5435-9 (1981)
	CA	Lee <i>et al.</i> , "Interferon- $\alpha_2$ Variants in the Human Genome," <i>J. Interferon and Cytokine Res.</i> 15: 341-349 (1995)
	CB	Masci <i>et al.</i> , "New and modified interferon alfas: preclinical and clinical data," <i>Curr. Oncol. Rep.</i> 5: 108-13 (2003)
	CC	NCBI Core Nucleotide AY255838
	CD	NCBI Protein AAA00949
	CE	NCBI Protein AAA52715
	CF	NCBI Protein AAA55468
	CG	NCBI Protein AAA55519
	CH	NCBI Protein AAA56191
	CI	NCBI Protein AAA75653
	CJ	NCBI Protein AAA94038
	CK	NCBI Protein AAB56781
	CL	NCBI Protein AAL01040
	CM	NCBI Protein AAP20099
	CN	NCBI Protein AAR45816
	CO	NCBI Protein AAR47404
	CP	NCBI Protein AAR47412

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17109-012001/922	Application No. 10/658,834
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Rene Gantier et al.	
		Filing Date September 8, 2003	Group Art Unit 1631
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/EGS/	CQ	NCBI Protein AAW12828
	CR	NCBI Protein CAA00410
	CS	NCBI Protein CAC88666
	CT	NCBI Protein CAD29057
	CU	NCBI Protein CAI94176
	CV	NCBI Protein CAI94186
	CW	NCBI Protein P01563 (SwissProt)
	CX	Nisbet <i>et al.</i> , "Single Amino Acid Substitutions at Conserved Residues of Human Interferon- $\alpha$ Can Effect Antiviral Specific Activity," <i>Biochemistry International</i> 11: 301-309 (1985)
	CY	Palmieri <i>et al.</i> , "Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report," <i>Oncol Rep.</i> 7: 145-9 (2000)
	CZ	Piebler, J. and G. Schreiber, "Mutational and Structural Analysis of the Binding Interface between Type I Interferons and their Receptor Ifnar2," <i>J. Mol. Biol.</i> 294: 223-237 (1999)
	DA	Radhakrishnan <i>et al.</i> , "Zinc mediated dimer of human interferon- $\alpha_{2b}$ revealed by X-ray crystallography," <i>Structure</i> 4: 1453-63 (1996)
	DB	Stennicke, H.R. and G.S. Salvesen, "Catalytic properties of the caspases," <i>Cell Death and Differentiation</i> 6:1054-1059 (1999)
	DC	Streuli <i>et al.</i> , "At Least Three Human Type $\alpha$ Interferons: Structure of $\alpha_2$ ," <i>Science</i> 209: 1343-7 (1980)
	DD	Takayama <i>et al.</i> , "Effects of oral administration of interferon-alpha on antibody production in mice with induced tolerance," <i>J Interferon Cytokine Res.</i> 19(8):895-900 (1999)
	DE	Uzé <i>et al.</i> , " $\alpha$ and $\beta$ Interferons and Their Receptor and Their Friends and Relations," <i>J Interferon and Cytokine Res</i> 15: 3-26 (1995)
	DF	Vogelmeier <i>et al.</i> , "Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity," <i>Chest</i> 110:261S-266S (1996)

Examiner Signature /Elly Gerald Stoica/	Date Considered 03/15/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	